UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Apple Turns 50: From Garage Startup to AI Crossroads 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Britain Courts Anthropic Amid US Defense Department Dispute 
NEWARK, Calif., Nov. 22, 2016 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will participate in a fireside chat at the 28th Annual Piper Jaffray Healthcare Conference scheduled for 2:00 pm ET (11:00 am PT) on Tuesday, November 29, 2016 in New York, New York.
The fireside chat will be webcast live and may be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the event will be archived for 30 days on the company's website.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
Investor Contact: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
